We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
May we actually help clinicians select the best systemic treatment for patients with intermediate-stage hepatocellular carcinoma?
- Authors
Giannini, Edoardo G.; Strazzabosco, Mario
- Abstract
This article examines the current state of systemic treatment for patients with intermediate-stage hepatocellular carcinoma (HCC) and highlights the lack of comparative studies between different treatment regimens. The authors present the findings of a retrospective study comparing lenvatinib and atezolizumab/bevacizumab in patients who were not suitable for trans-catheter arterial chemoembolization (TACE). The study reveals similar overall survival and objective response rates between the two treatments, with atezolizumab/bevacizumab showing improved progression-free survival. However, the study has limitations, and further research is necessary to determine the optimal systemic treatment for patients with intermediate-stage HCC. The document includes a conflict of interest statement, data availability statement, and references to related studies on HCC treatment. It also emphasizes the importance of considering liver function when selecting systemic therapy for advanced HCC.
- Subjects
HEPATOCELLULAR carcinoma; MEDICAL personnel
- Publication
Liver International, 2024, Vol 44, Issue 2, p272
- ISSN
1478-3223
- Publication type
Article
- DOI
10.1111/liv.15781